USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CYTOCURE, LLC
Address:
100 CUMMINGS CENTER, STE 430C
BEVERLY, MA 01915-
Phone:
N/A
URL:
N/A
EIN:
43476521
DUNS:
154689538
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $950,786.00 5

Award List:

REVERSAL OF 'ANTIGEN-SILENCING' FOR CANCER THERAPY

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$250,000.00
Agency:
HHS
Principal Investigator:
Paul J. Durda
Abstract:
DESCRIPTION: (Applicant's Description) oxide synthase; iNOS) has been implicated in the pathogenesis of various forms of inflammation. Chronic inflammation is a known risk factor for carcinogenesis. There are multiple lines of… More

GFP-REPORTER CONSTRUCTS FOR TUMOR ANTIGEN REGULATION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$168,700.00
Agency:
HHS
Principal Investigator:
Abstract:
The goals of this Phase I project are to develop stable melanoma cell lines containing a reporter gene linked to the Melan-NMART-1 promoter for use in high throughput drug screening. We propose to develop these cell lines to identify drugs that up-regulate Melan-A/MART-1 expression. Loss of tumor… More

TRANSCRIPTION REGULATION OF MELANOMA ANTIGEN EXPRESSION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall aim of this Phase I proposal is to devise therapeutic modalities which will assure constitutive expression of antigenic proteins needed for effective cell-mediated immunity against the tumor cells. These studies will focus on the regulation of genes… More

HTS for agents that increase recognition of tumors by cytotoxic lymphocytes

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$132,086.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ultimate aim of this proposal is to design improved therapies for malignant melanoma. This proposal will promote the development of a High Throughout Screening (HTS) system for assessing cell mediated cytotoxicity a gainst human tumor cells, which is a… More

Combination Melanoma Immunotherapy: Antigen Enhancement and Adoptive T Cells

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Estelle E. Newton – 978-232-1243
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this proposal is to develop agents to increase the efficacy of immunotherapy of malignant melanoma. The studies in this proposal involve a proof-of-principle combination immunotherapy protocol in amouse model, using drugs to increase antigen… More